Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin

Purpose The aim of this study was to compare incidence rates of heart failure, stroke, and acute myocardial infarction (AMI) in Type 2 diabetic patients using different types of insulin. Methods Included were patients with a diagnosis of Type 2 diabetes and at least one insulin prescription from May...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoepidemiology and drug safety 2009-06, Vol.18 (6), p.497-503
Main Authors: Juhaeri, Juhaeri, Gao, Shujun, Dai, Wanju S.
Format: Article
Language:English
Subjects:
Acute Disease
acute myocardial infarction
Adult
Aged
Aged, 80 and over
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - epidemiology
Cohort Studies
Diabetes Mellitus, Type 2 - drug therapy
epidemiology
Female
heart failure
Heart Failure - chemically induced
Heart Failure - epidemiology
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Incidence
Insulin - adverse effects
Insulin - analogs & derivatives
Insulin - therapeutic use
Insulin Glargine
Insulin, Isophane - adverse effects
Insulin, Isophane - therapeutic use
Insulin, Long-Acting - adverse effects
Insulin, Long-Acting - therapeutic use
Male
Middle Aged
Myocardial Infarction - chemically induced
Myocardial Infarction - epidemiology
Retrospective Studies
stroke
Stroke - chemically induced
Stroke - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The aim of this study was to compare incidence rates of heart failure, stroke, and acute myocardial infarction (AMI) in Type 2 diabetic patients using different types of insulin. Methods Included were patients with a diagnosis of Type 2 diabetes and at least one insulin prescription from May 2001 to July 2007. Incidence rate ratios (RRs) of heart failure, stroke, and AMI were estimated using Poisson regression with adjustment for age, gender, history of hypertension, dyslipidemia history, days supply, and duration of diabetes. Results Incidence rates of heart failure, stroke, and AMI in the insulin glargine group were 306.9 (95%CI: [278.9, 334.8]), 174.8 (95%CI: [153.7, 195.8]), and 105.2 (95%CI: [88.9, 121.5]) cases per 10 000 person–years, respectively. After adjustment for covariates, the incidence rates of CVD events in the insulin glargine were comparable to those in the other long/intermediate acting insulin group (reference), except for AMI, which tended to be lower in the insulin glargine group (RR = 0.81, 95%CI: [0.65, 1.02]). Using the same reference, the incidence rate of stroke was higher in patients taking rapid/short acting insulin, premixed insulin, or mixed use of insulin except insulin glargine (RR = 1.20, 95%CI: [1.04, 1.40]). Conclusion This study suggested that insulin glargine use might be associated with a lower risk of AMI, compared to the other long/intermediate acting insulin use, and that insulin regimen of rapid/short acting insulin, premixed insulin, or mixed use of insulin except insulin glargine was associated with a higher risk of stroke using the same reference. Copyright © 2009 John Wiley & Sons, Ltd.
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.1741